Tele: 561.316.3330
Breaking Medical Device News

Monday, September 20, 2021

MEDICAL DEVICE NEWS MAGAZINE

A DIGITAL PUBLICATION FOR THE PRACTICING MEDICAL SPECIALIST, INDUSTRY EXECUTIVE AND INVESTOR
HomeEXECUTIVESCharles J. Fisher, Jr., M.D. New CEO of Aethlon Medical: Brings to the Table Experience In Financing, Structuring Corporate Deals, Clinical Development and Regulatory Strategy

Charles J. Fisher, Jr., M.D. New CEO of Aethlon Medical: Brings to the Table Experience In Financing, Structuring Corporate Deals, Clinical Development and Regulatory Strategy

November 3, 2020

Charles J. Fisher, Jr., M.D. has been appointed the new chief executive officer of Aethelon Medical.  His appointment became effective on October 30, 2020.

Charles J. Fisher, Jr., M.D.  joined Aethlon as a member of Aethlon’s Board of Directors and has served as Chairman of the Board since November 2017. Mr. Ed Broenniman replaced Dr. Fisher as the Chairman of the Board effective as of October 30, 2020. Dr. Fisher brings an impressive record of results in global, strategic and operational roles to Aethlon. Dr. Fisher succeeds Dr. Timothy Rodell, who will serve as a consultant to Aethlon during the transition.

 

Dr. Fisher’s experience as Head, Section of Critical Care Medicine at The Cleveland Clinic Foundation and his research in sepsis, inflammation, host defense and endothelial dysfunction led to his recruitment to Eli Lilly & Co., where he led the Xigris (activated Protein C) Global Product Team and successfully registered the first drug approved for the treatment of sepsis. Dr. Fisher served as Vice President for Global Pharmaceutical Development at Abbott Laboratories where, among other accomplishments, he guided the registration of Humira.

Dr. Fisher also served as Executive Vice President and Chief Medical Officer at Cardiome Pharma, where he led multiple clinical trials for Brinavess, resulting to its approval in Europe and a global strategic transaction with Merck and Co. for $800 million US dollars.

Additionally, Dr. Fisher has served as a member of the Defense Science Research Council and on DARPA panels, including one focused on universal host defense. Aethlon’s Board of Directors believes these experiences will enable Dr. Fisher to guide Aethlon’s development and commercialization of the Hemopurifier.

“We are delighted to begin our next chapter at Aethlon with Charles J. Fisher, Jr., M.D. as our CEO,” said Mr. Broenniman, Chairman of Aethlon’s Board of Directors. “Chuck’s depth and breadth of experience in financing, structuring corporate deals, clinical development and regulatory strategy, both in the U.S. and internationally, will be of great value as we prepare Aethlon for the next phase of development.”

“I am both honored and excited to take over this role at Aethlon at this time,” said Dr. Fisher. “I believe the Aethlon Hemopurifier has great potential for treating life-threatening viral infections including Covid-19 and potentially cancer. We are now open to enrolling patients in our first clinical trial in advanced and/or metastatic head and neck cancer at the UPMC Hillman Cancer Center in Pittsburgh, PA. Also under an Investigational Device Exemption (IDE) we are now opening sites for our trial to treat patients with SARS-CoV-2/COVID-19 infection. I look forward to working with the team at Aethlon and its collaborators to continue to advance the science and in an effort to bring important treatments to patients and create value for shareholders.”

“I’m proud to have led Aethlon for the past 2 years”, said Dr. Rodell. “I am pleased to hand the reins to Chuck to lead the next phase of Aethlon’s growth, and I wish him and the leadership team every success.”

Dr. Fisher commented, “On behalf of the Board of Directors, I want to thank Tim for his leadership, commitment and accomplishments as Chief Executive Officer. We wish him continued success in his future endeavors.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected

spot_img

Don't Miss

Mark Foster Joins Xenocor BOD

Foster is a versatile and visionary C-Suite executive who brings 20 years of general management and leadership experience from both venture-backed growth-stage organizations and world-class medical device companies

Hinge Health Acquires the Most Advanced Computer Vision Technology for Tracking Human Motion

CEO Daniel Perez explained, “We won’t stop investing in technology to deliver the most patient-centered digital clinic that improves member experience and outcomes while reducing costs. wrnch allows us to take a giant leap forward in all respects.”

Dale W Wood Congratulates the Huma Team on Raising $130 Million

Major health and technology companies across the world have committed upwards of $130 million to Huma Therapeutics, the health-tech company backed by Dale Ventures.

Rhaeos Awarded $4 Million NIH SBIR Grant

Under the NIH SBIR grant, Rhaeos will leverage their existing wireless sensor hardware to provide additional quantitative flow data to the clinician, giving insight into this currently inaccessible and highly relevant shunt performance metric.

Gynesonics Announces FDA Clearance of Next Generation Sonata System

“This clearance brings significant system improvements that expand the location of fibroids that can be treated while allowing the physician to control all aspects of the treatment from within the sterile field,” said Jiayu Chen, Ph.D. Vice President, Engineering and Advanced Technologies at Gynesonics.

Blackrock Neurotech Invests In Groundbreaking Auditory Nerve Implant With University Of Minnesota And MED-EL

The new investment will enable the development and translation of a new ANI through preclinical studies and later, a pilot clinical trial, where the ANI is then implanted in up to three deaf patients.

Jonathan Chapman: New President/CEO of Trividia Health

Chapman said, “I’m honored to join the Trividia team as President and CEO. This organization has a long history of leadership within the healthcare industry as a provider of accurate, accessible, and affordable point-of-care solutions for the management of diabetes.”

SOLOPASS® System (Bedside Neuro-Navigation Device) Receives FDA 510(k) Clearance

inTRAvent’s SOLOPASS® system brings simple, portable, bedside neuro-navigation into the intensive care unit.

By using this website you agree to accept Medical Device News Magazine Privacy Policy